PYPD

PolyPid Ltd.

Healthcare
Biotechnology
$98M market cap

Forecast run · Sep 14, 2026Upside rank 1072 of 3,136

Model Signal

ForecastQ Daily Probabilities

43.6%

48.0%

18.1%

Analyst Consensus

Recommendation2.11/5 Buy

Last price$5.15

Price target$12.50

Implied move+142.7%

Analysts9

ForecastQ Portfolios

PYPD is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.